GlassScriptPhysician profile
Jeffrey Gotschall
NPI 1174525414
$1,912.56
in general payments reported to CMS, 2019-2025
29 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $339 · 2021: $251 · 2022: $151 · 2023: $73.41 · 2024: $161 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $265.35 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $243.95 | 2019-2025 | Airsupra |
| Allergan, INC. | $212.10 | 2019-2020 | |
| Amgen INC. | $165.64 | 2019-2024 | Otezla, Repatha |
| Inspire Medical Systems, INC. | $163.24 | 2025 | Inspire |
| Pfizer INC. | $155.05 | 2019-2025 | |
| Lilly USA, LLC | $82.49 | 2020-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.91 | 2020-2025 | Jardiance |
| Abbvie INC. | $60.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $47.55 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.56 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.88 | 2021-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Janssen Pharmaceuticals, INC | $37.87 | 2019 | |
| Abbott Laboratories | $36.46 | 2023-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $34.41 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $24.94 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $23.97 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.70 | 2024 | Opsumit, Uptravi |
| Upsher-Smith Laboratories LLC | $18.78 | 2020 | |
| Medicure Pharma INC. | $17.73 | 2021 | |
| Genentech USA, INC. | $16.81 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.43 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $16.21 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.05 | 2025 | Xifaxan |
| Depuy Synthes Sales INC. | $15.92 | 2019 | |
| Esperion Therapeutics, INC. | $15.47 | 2024 | Nexletol |
| Avanir Pharmaceuticals, INC. | $14.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gotschall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.